HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Industry Report - Insights on China Medical Beauty Industry

China Healthcare Policy Update - The Official Results of 2020 Medical Insurance Negotiations

JD Health (6618.HK) - Opportunities Coexist with Challenges

Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?

Pre-IPO Basecare Medical - Here Are the the Strengths and Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Raily Aesthetic Medicine International Holdings Limited / Equity Capital Markets

Raily Aesthetic Medicine International Holdings Limited (2135 HK)

Raily Aesthetic Medicine International Holdings Limited

On December 15th, <a href="https://www.smartkarma.com/entities/raily-aesthetic-medicine-international-holdings-limited" target="_blank" data-smartkarma-citation="entities:31100:1" rel="noopener">Raily Aesthetic Medicine (2135 HK)</a> began to raise capital by floating shares. The Company planned to issue 342.5 million shares at an issue price of HK$0.3-0.4 per share, with a corresponding market value of HK$617 million - HK$822 million. Raily is expected to go public on December 28th. Whether the Company could develop smoothly after going public is worth the attention of the capital market.

On December 15th, Raily Aesthetic Medicine (2135 HK) began to raise capital by floating shares. The Company planned to issue 342.5 million shares at an issue price of HK$0.3-0.4 per share, with a corresponding market value of HK$617 million - HK$822 million. Raily is expected to go public on December 28th. Whether the Company could develop smoothly after going public is worth the attention of the capital market. 

Pre-IPO Raily Aesthetic Medicine (2135.HK) - Here Are the Concerns